Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

Source Summary

Basel, 29 June 2026 — Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of AXELIOS 1 based on the innovative SBX technology, with a unique combination of accuracy, speed, flexibility, scalability and cost efficiency that addresses critical bottlenecks in genomics and potentially in clinical research. AXELIOS 1 will enable researchers to make significant discoveries that enhance our understanding of diseases, with the potential to replace existing technologies in pivotal research areas.